Mizuho raised the firm’s price target on Immuneering (IMRX) to $12 from $10 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Two new option listings and three option delistings on October 2nd
- Immuneering’s Promising Phase 2a Data and Safety Profile Drive Buy Rating
- Immuneering Announces Public Offering to Raise $164.1M
- Immuneering price target raised to $30 from $21 at Oppenheimer
- Immuneering 18.96M share Spot Secondary priced at $9.23